ImmunoCellular (OTC: IMUC.OB): Updated Presentation, Pending Catalysts

ImmunoCellular Therapeutics (OTC: IMUC.OB) is developing an off-the-shelf (i.e. does not require obtaining cells from the patient as part of the manufacturing process) peptide-based, cancer stem cell vaccine / immunotherapy (ICT-121) which targets a protein marker called CD133 that is over-expressed on cancer stem cells.